+1 2315155523
Sector Data Insights (SDI) is a specialized market intelligence and strategic consulting firm focused on delivering high-quality, data-driven syndicated research reports, industry analysis, competitive intelligence, and advisory solutions. With a strong emphasis on analytical excellence, particularly in life sciences, analytical instrumentation, and related high-tech sectors, Sector Data Insights empowers manufacturers, investors, service providers, researchers, and decision-makers with actionable insights for strategic growth, innovation, and market leadership.
SDI combines deep domain expertise in laboratory and analytical technologies with advanced analytics to provide comprehensive market assessments, technology trend analysis, vendor share data, investment intelligence, supply chain insights, and forward-looking forecasts. Our research supports organizations navigating complex global markets across industries such as life sciences, semiconductors & electronics, consumer goods, materials & chemicals, construction & manufacturing, food & beverages, energy & power, automotive & transportation, ICT & media, aerospace & defense, and BFSI.
Remicade (Infliximab) Monoclonal Antibody.jpg){kind=small}
Research Analyst
| Metric | Value |
|---|---|
| Base Year Valuation | USD 0.8 Billion |
| Forecast Valuation | USD 1.25 Billion |
| CAGR | 5.1% |
| Forecast Period | 2026-2034 |
| Largest Regional Market | North America |
| Dominant Segment | Biosimilar |
-Monoclonal-Antibody.png)
Global expenditure on infliximab and its biosimilars will expand at a 5.1% compound annual growth rate from USD 0.8 billion in 2025 to USD 1.25 billion by 2034. Growth is concentrated in patient segments where switching protocols are widely accepted and in emerging markets where biologic access is broadening. The Monoclonal Antibody Market dedicated to infliximab is transitioning from a single-brand biologic to a multi-biosimilar ecosystem. Although the base year valuation stands at USD 0.8 billion, the use of biosimilar infliximab has pushed volume levels above those of the originator Remicade in many European and Asian markets. The remaining two-thirds of sales are still captured by brand-name infliximab in the United States, but this share will face sustained erosion as more payers implement step therapy protocols that mandate biosimilar-first access. The Autoimmune Disease Therapeutics Market is expanding at an 8-10% rate for non-TNF biologic mechanisms, yet infliximab maintains a durable niche because of deep evidence in inflammatory bowel disease and refractory rheumatoid arthritis. Strategic growth drivers include the expansion of subcutaneous formulations, which reduce infusion-center visit burden and make home-based administration feasible. At the same time, pricing pressure from biosimilar competition is lowering the average net cost per patient-year, allowing more patients to remain on therapy and offsetting revenue decline with volume. The forecast valuation of USD 1.25 billion reflects a cautiously optimistic scenario in which emerging markets in Asia-Pacific become the primary growth engine. The dominant biosimilar segment will soon account for more than 60% of global infliximab doses, even if value-based share remains below half because of list-price differences. Providers, payers, and patients are all adapting to a market structure where switching between biosimilars is routine and dosing intervals are being optimized with therapeutic drug monitoring. The report forecasts that the combined effects of patent expiration, new biosimilar entrants, and clinical trial expansions will keep the CAGR at a moderate 5.1% rather than a double-digit pace. Key executives in the Tumor Necrosis Factor Inhibitors Market should watch for oligopoly consolidation among biosimilar manufacturers, as only Celltrion, Samsung Bioepis, and Pfizer have the scale to profitably supply global markets.
-Monoclonal-Antibody.png)
The Infliximab Biosimilar Market is expanding at an estimated 8.4% CAGR, outweighing the 1.2% growth of branded infliximab. In 2025, biosimilars captured 55% of European infusion volume and 46% of North American volume, but only 32% of global revenue due to discounts averaging 58% against the originator's list price. Hospital tenders for biosimilar infliximab now account for nearly 3 out of every 4 prescriptions across major outpatient infusion centers. The revenue gap will narrow by 2030 as second-generation biosimilar contracts maintain pricing discipline and key patents expire across Latin America.
Within the Crohn's Disease Treatment Market, infliximab remains a standard-of-care induction and maintenance therapy for moderate-to-severe disease. Real-world switching studies from Europe demonstrate that clinical outcomes are equivalent when patients transition from Remicade to biosimilar CT-P13 or SB2, which has increased prescriber confidence. The Rheumatoid Arthritis Biologic Drugs Market is the second-largest revenue pool, where infliximab competes with tumor necrosis factor (TNF) inhibitors such as etanercept and adalimumab. Due to lower acquisition costs, biosimilar infliximab is being positioned as a cost-effective first-line biologic for patients with no prior biologic exposure, particularly in countries requiring cost-effectiveness documentation. Ankylosing spondylitis contributes around 10% of segment volume, while other inflammatory conditions such as ulcerative colitis and psoriasis are gaining share due to off-label evidence.
Biosimilar adoption will continue to rise, but the margin per patient visit is falling. Reimbursement rates in the U.S. Medicare program are set to average sales price plus 6%, which compresses the buy-and-bill margin historically used by community practitioners. The margin pressure is pushing consolidation among oncology and infusion centers, which are using scale to negotiate rebates on the entire Tumor Necrosis Factor Inhibitors Market. Overall, the biosimilar segment is projected to account for 67% of total infliximab dose volume by 2034, up from 51% in 2025.
North America remains the largest revenue contributor with roughly 40% of global value, driven by the United States, where pricing power and high biologic adoption exist. In 2025, U.S. infliximab sales are split 68% brand and 32% biosimilar, and the biosimilar share could reach 55% by 2030. The U.S. regulatory environment, shaped by FDA guidance and the BPCIA, provides a 12-year exclusivity period, but no new biosimilar infliximab patents are blocking near-term entry. Europe accounts for approximately 30% of global revenue, with the UK, Germany, and France serving as the primary volume hubs. Biosimilar penetration in Europe is the highest among all regions, surpassing 80% in Germany and Norway. The EU regulatory regime mandates biosimilar extrapolation to all approved indications, supporting switching. Asia-Pacific is the fastest-growing corridor, expected to post a 7.2% CAGR from 2026 to 2034. China, India, and ASEAN markets are expanding due to growing diagnostic capability and local biosimilar manufacturing. China's National Medical Products Administration requires local pharmacokinetic and pharmacodynamic bridging studies, but domestic biosimilar approvals have shortened to 2-3 years. South America and Middle East & Africa together contribute around 8% of the global market, with Brazil anchoring Latin America. Brazil's health regulatory agency allows indicative biosimilar pathways, and government tenders have made infliximab biosimilars widely available. The most mature market is Western Europe, where biosimilar substitution is near saturation, while the fastest-growing is Asia-Pacific, driven by expanding specialty care infrastructure.
-Monoclonal-Antibody.png)
The end-user base is split across four buyer groups: hospital infusion centers, private infusion clinics, specialty pharmacies, and self-pay patients in emerging markets. Hospitals and integrated healthcare systems prioritize total cost of care and prefer biosimilar infliximab due to reimbursement margin floors. Private specialty clinics, particularly in the U.S., favor brands when reimbursement spread is positive, but are shifting to biosimilar contracts under payer mandate. Specialty pharmacy procurement is consolidating; the top five pharmacy benefit managers now manage over 70% of infliximab prescriptions. Price elasticity is low for medically necessary infliximab, but high for biosimilar selection once interchangeability is established. Digital purchasing habits are changing through online specialty pharmacy portals and telehealth-driven prescriptions, which lower out-of-pocket costs and support home infusion. Providers also use therapeutic drug monitoring data to switch dosage forms, and patient support programs are becoming a critical decision factor, especially in biosimilar-saturated markets. Buyers increasingly demand outcomes-based contracts, with rebates linked to patient persistence and disease-restriction scores.
The upstream production chain for infliximab relies on Chinese hamster ovary (CHO) cell lines, cell culture media, disposable bioreactor bags, and purification resins. Cell culture media accounts for 15-20% of total production cost, and the Cell Culture Media Market has seen API-grade media price increases of 4-8% per year because of raw material shortages, especially amino acids and growth factors. Downstream purification uses Protein A affinity chromatography as the primary capture step; the Protein A Chromatography Market is becoming a bottleneck, with resin suppliers like Cytiva and Thermo Fisher extending lead times from 4 to 10 weeks over the past two years. In addition, single-use bioprocess containers are highly reliant on polymeric films from specialized suppliers, creating both price and geopolitical supply risk. The broader Biologics Manufacturing Market is transitioning from batch to continuous processing, which reduces Protein A resin consumption by up to 25% per gram of antibody produced. Contract manufacturing organizations are investing in integrated cell-line engineering to screen clones that express high stable titers. Logistics risk remains high for cold-chain distribution, since infliximab must be stored at 2-8°C, and emerging-market distribution incurs 15-20% wastage rates in regions lacking reliable infrastructure. The report identifies active pharmaceutical ingredient (API) supply concentration in South Korea, Ireland, and the United States as a key risk; a disruption at any of the top three production sites could delay global supply for 6-9 months. Consequently, buying organizations are dual-sourcing biosimilars and increasing inventory safety stock to 12-16 weeks.
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 5.1% from 2020-2034 |
| Segmentation |
|
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
Remicade (Infliximab) Monoclonal Antibody, by Application (Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn's Disease, Other), by Types (Brand, Biosimilar), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific), Forecast 2026-2034
| Stakeholder Role | Interview Share (%) |
|---|---|
| Procurement Directors | 30% |
| Regulatory Affairs Managers | 25% |
| Clinical Program Leads | 20% |
| Hospital Pharmacy Directors | 15% |
| Manufacturing Operations Heads | 10% |
| Company Type | Representation (%) |
|---|---|
| CDMOs & Biologic Manufacturers | 35% |
| Regulatory & Clinical Research Organizations | 25% |
| Raw Material & Equipment Suppliers | 20% |
| Healthcare Providers & Infusion Centers | 15% |
| Specialty Payers & Pharmacies | 5% |
FDA and EMA require extensive immunogenicity and extrapolation studies for infliximab biosimilars. The EMA has approved more than 10 infliximab biosimilars, while the FDA has approved four, and these differing requirements shape patient label claims and switching policies.
Biosimilar infliximab launched in the United States at a 36% discount to Remicade, and realized net prices have fallen by up to 55% from 2016 to 2023. Manufacturing costs remain high at roughly $95-$200 per gram, driven by CHO cell culture and Protein A purification.
Payer step therapy policies and lower out-of-pocket costs have pushed biosimilar infliximab to 47% of U.S. prescriptions by volume in 2023. Providers are also moving toward subcutaneous infliximab, which reduces infusion chair time and supports home administration.
Critical inputs include CHO cell lines, cell culture media, fetal bovine serum, and Protein A chromatography resins. During the COVID-19 pandemic, resin and media shortages extended production lead times by 8-12 weeks and single-use bag prices increased by 15-20%.
North America holds approximately 40% of global market value, driven by high biologic utilization and private payer coverage. Medicare reimbursement policies have accelerated biosimilar uptake but also compressed net prices.
Continuous manufacturing and high-throughput clone selection have reduced infliximab production costs by 25-30% in the last decade. The arrival of subcutaneous infliximab, such as CT-P13 SC, enables at-home administration and is expanding the treatable patient population.